You cannot and should not "dilute" voriconazole film-coated tablets—this formulation is not designed for splitting, crushing, or compounding.
Critical Formulation Issue
Film-coated tablets are manufactured as intact dosage forms and should not be manipulated. Voriconazole 50 mg tablets are designed to be swallowed whole. Attempting to split, crush, or create a suspension from film-coated tablets will:
- Destroy the film coating (which may affect stability and absorption)
- Result in inaccurate and inconsistent dosing
- Potentially alter the pharmacokinetics unpredictably
- Create medication errors in a drug with a narrow therapeutic index
Practical Solutions for 80 mg Dosing
Option 1: Use Available Tablet Strengths (Preferred)
- Give one 50 mg tablet + one additional 50 mg tablet, then adjust based on therapeutic drug monitoring (TDM)
- Initial dose: 100 mg twice daily (closest available dose using whole tablets)
- This slightly higher dose (100 mg vs 80 mg) is acceptable given that:
Option 2: Request Oral Suspension
- Contact your pharmacy to obtain voriconazole oral suspension (if available in your region)
- Oral suspension allows precise dosing of 80 mg
- However, be aware: Oral administration in pediatric patients results in significantly lower plasma concentrations compared to IV 2
- Higher oral doses are typically required (often 9 mg/kg twice daily or even three times daily in young children) 5, 3
Option 3: Consider IV Formulation
- If precise dosing is critical and oral suspension unavailable, consider IV voriconazole
- IV allows exact mg/kg dosing
- Switch to oral once therapeutic levels achieved and clinical improvement documented 1
Essential Monitoring Requirements
Regardless of which option you choose, therapeutic drug monitoring is mandatory 6, 4:
- Obtain trough concentrations at steady state (after 5-7 days or after dose changes)
- Target range: 1-5 μg/mL (some sources suggest 1-5.5 μg/mL) 4, 7
- For prophylaxis: Minimum 0.5-1 μg/mL may be acceptable 8
- For treatment: Aim for ≥1-1.5 μg/mL 7
Critical Pediatric Considerations
Children require substantially higher weight-based doses than adults 2, 9, 3:
- Younger children have faster voriconazole clearance
- Oral bioavailability is more variable in pediatrics
- Children <12 years often need 15-25 mg/kg/day in divided doses 3, 10
- Children ≥12 years typically need 9-14 mg/kg/day 3
- Multiple dose adjustments are frequently required 3, 10
Common Pitfalls to Avoid
- Never crush or split film-coated tablets for "precise" dosing—this creates more problems than it solves
- Don't assume adult dosing applies to children—pediatric pharmacokinetics are fundamentally different 9
- Don't skip TDM—50% of pediatric patients fail to achieve therapeutic concentrations with initial dosing 3
- Don't use the same target for prophylaxis and treatment—therapeutic indications require different concentration thresholds 8
- Monitor for CYP2C19 polymorphisms and drug interactions—these significantly affect voriconazole levels 6, 4, 7
Recommended Action Plan
- Start with 100 mg (two 50 mg tablets) twice daily as the closest available dose
- Obtain baseline liver function tests before initiating therapy 1
- Measure steady-state trough concentration after 5-7 days
- Adjust dose based on TDM results and clinical response
- Monitor for visual disturbances, hepatotoxicity, and neurologic effects 11
- Consider switching to oral suspension if available for more precise dosing flexibility
The key message: Precise initial dosing is less important than achieving therapeutic concentrations through TDM-guided adjustments. Film-coated tablets cannot be safely manipulated for fractional dosing.